Appeals Court Revives Teva's Breach Suit Against Lilly Over Forteo Generic Delay
LLY sits 91% above its 52-week low of $623.78 on light trading volume (0.3× avg).
Summary
A federal appeals court revived Teva's lawsuit accusing Lilly of breaching a 2018 settlement that allowed Teva to sell a generic version of osteoporosis drug Forteo. The lower court had dismissed the case, ruling the agreement expired before Lilly allegedly broke it. The 7th Circuit reversed, finding the contract's expiration date ambiguous and sending the case back for further proceedings. Teva claims Lilly's 2020 FDA exclusivity extension unlawfully delayed its generic launch until December 2023. The revived litigation introduces uncertainty around potential damages or an injunction, though Forteo is a mature product. No immediate financial impact is quantified, but the legal risk could weigh on Lilly's stock near its 52-week high.
At the time of this announcement, LLY was trading at $1,188.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.